Genetic polymorphisms of CYPIA1 and GSTM1 and lung cancer risk

Susceptibility to lung cancer may, in part, be determined by interindividua l differences in the cytochrome P450-catalysed bioactivation and the glutat hione S-transferase-catalysed detoxification of procarcinogens. Therefore a lung cancer case-control study was set up to investigate the association o f three polymorphisms of the CAP1A1 gene (CYP1A1*2A, CYP1A1*2B, CYP1A1*4) a nd GSTM1*0 genotype with lung cancer risk in Austrian Caucasians. Genomic D NA was isolated from the peripheral blood lymphocytes of 134 male lung canc er patients and 134 age-matched controls with nonmalignant conditions and P CR-based analyses were performed. There was no significant difference in ri sk between cases and controls, either for the CYP1A1*2A (OR=1.09, 95%CI=0.4 6-2.58), CYP1A1*2B (OR=1.09, 95%CL=0.46-2.58) or for the CYP1A1*4 polymorph ism (OR=0.49, 95%CL=0.20-1.16). The prevalence of the GSTM1*0 genotype in t he lung cancer group (478%) was comparable to that found in the control gro up (49.3%) and also had no effect on lung cancer risk (OR=0.94, 95%CL=0.54- 1.57). Further, in a subgroup of male ever-smokers (n=126). no significant influence on the relative risk was found for these polymorphisms. Our resul ts suggest that these investigated polymorphisms can not be considered as g enetic susceptibility markers for lung cancer within the Austrian Caucasian population.